| Assessment Status | Full HTA Assessment |
| HTA ID | - |
| Drug | Roflumilast |
| Brand | Daxas® |
| Indication | For the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations. |
| Assessment Process | |
| Full submission received from Applicant | 11/06/2010 |
| NCPE assessment completed | 03/11/2010 |
| NCPE assessment outcome | Reimbursement not Recommended |
We do not recommend reimbursement of Roflumilast (Daxas®) under the Community Drugs Schemes.